Epinephrine Cyclops®

About PureIMS

PureIMS is a private, clinical-stage biotech leveraging its proprietary Cyclops® dry powder inhaler platform to develop inhaled therapies for respiratory and systemic conditions. Its lead program, Colistin Cyclops®, is already marketed under a named patient regimen in the Netherlands for cystic fibrosis, with over 100,000 doses prescribed, demonstrating early commercial traction. The company has a pipeline including programs for Parkinson's disease and anaphylaxis, and it actively pursues co-development partnerships, supported by a seasoned management team and non-dilutive grant funding.

Therapeutic Areas